Ennature Bio Pharma posts ₹4.89 Cr PAT in debut quarter, reverses year-ago loss
revenue +44.92% · margins expanding
₹78.46 Cr
+44.92% YoY
₹4.89 Cr
6.23%
₹2.19
Ennature Bio Pharma, reporting its first results since listing on NSE and BSE on November 4, 2026, posted standalone revenue from operations of ₹78.46 Cr for Q2 FY27, up 44.9% YoY from a restated ₹54.14 Cr in Q2 FY26, though down 13.2% sequentially from ₹90.39 Cr in Q1 FY27. PAT came in at ₹4.89 Cr — a clean YoY turnaround from a ₹1.28 Cr net loss a year earlier — and up 4.9% QoQ from ₹4.66 Cr in Q1 FY27. There are no brokerage previews or consensus estimates available for this stock, which has been listed for barely over a week, so the print cannot be benchmarked against the street; vsStreet is unknown. Management has placed no formal guidance or outlook on record either, so vsGuidance is also unknown at this stage.
Q2 FY-2027 vs prior quarters
No year-ago quarter on record — YoY cells may be blank.
Net profit margin expanded sharply to 6.23% from -2.37% in the loss-making year-ago quarter and from 5.15% in Q1 FY27. EBITDA margin (reported as Profit Before Interest, Depreciation and Tax) rose to 13.18% from 11.15% YoY and 11.04% QoQ, even as revenue fell sequentially — pointing to cost discipline rather than volume-driven operating leverage. Cost of materials consumed fell to ₹31.09 Cr (39.6% of revenue) from ₹60.79 Cr (67.2% of revenue) in Q1 FY27, the single biggest driver of the margin step-up. There were no exceptional items in the quarter (unlike the ₹0.28 Cr exceptional item in FY26 full-year), so the swing to profit is on a like-for-like operating basis, not a one-off.
What the summary numbers don't show
EPS ₹2.19 (not annualised) vs ₹2.09 in Q1 FY27 and -₹0.57 in Q2 FY26
Comparative-period figures are restated/unaudited, sourced from India Glycols' Biopharma-undertaking books — not reviewed by current statutory auditors
These are Ennature's first results as an independently listed company following the NCLT-approved demerger of the Biopharma undertaking from India Glycols Limited — effective September 1, 2026 with an April 1, 2026 appointed date — and its subsequent listing on NSE and BSE on November 4, 2026, per our event records. The trading-window closure around the November 12 board meeting and the listing itself are the only corporate developments on record this quarter; neither has a direct numeric read-through beyond context. No management press release or earnings commentary has been captured for this filing, so there is no management framing to reconcile against the numbers.
W1
Sequential revenue trend: Q2 FY27 fell 13.2% QoQ to ₹78.46 Cr from ₹90.39 Cr in Q1 FY27 — watch whether Q3 FY27 reverses or confirms a slowdown
W2
Margin sustainability: EBITDA margin jumped to 13.18% this quarter from ~11% in the prior two quarters — confirm whether this is a new run-rate or quarter-specific
W3
No management guidance or concall on record yet for this newly listed entity — first forward-looking commentary from management will be a key marker
Filing has only a standalone statement (single entity, single segment, no subsidiaries). Comparative figures for Q1 FY27, Q2 FY26 and FY26 are restated numbers extracted from India Glycols Ltd's Biopharma-undertaking books per the NCLT-approved demerger (effective 1-Sep-2026) and have NOT been independently audited/reviewed by the company's statutory auditors — only the current quarter carries a limited-review opinion. Minor OCR inconsistency in the year-ago PBT line (661.15 vs printed 136.00/136.04 variants) does not affect the current-period column used here.